Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Yantai Dongcheng Pharma Gets FDA Go-Ahead for 177Lu-LNC1004 Clinical Trial

Fineline Cube Jan 9, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

VivaVision Biotech Partners with Everads Therapy for Retinal Disease Therapies

Fineline Cube Jan 9, 2023

China’s VivaVision Biotech Inc. has announced a collaboration agreement with Israel-based Everads Therapy Ltd to...

Company Deals

Shenzhen-Based Rhegen Bio Raises RMB 100 Million in Pre-Series B Round

Fineline Cube Jan 9, 2023

Shenzhen-based biotechnology company Rhegen Bio, specializing in mRNA technology, has reportedly raised RMB 100 million...

Company Drug

Hainan Poly Pharm’s Generic Ganciclovir Approved in Denmark

Fineline Cube Jan 9, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Jacobio Pharma Doses First Patient in US Phase I/IIa Study for JAB-2485

Fineline Cube Jan 9, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that the first patient has been dosed in...

Company Deals

VACSERA in Talks with Sinovac to Establish Integrated Vaccine Plant

Fineline Cube Jan 9, 2023

Egypt-based drug firm Holding Company for Biological Products and Vaccines (VACSERA) is reportedly in talks...

Company Drug

Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval

Fineline Cube Jan 9, 2023

Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...

Company Drug

Dizal’s Sunvozertinib and Golidocitinib Combo Gets NMPA Approval for Phase II Study

Fineline Cube Jan 9, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving approval from the National Medical...

Company Drug

Luye Pharma’s BA1301 Receives CDE Approval for Clinical Trials

Fineline Cube Jan 9, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval from the Center...

Policy / Regulatory

China’s National Health Commission Releases Updated COVID-19 Treatment Plan

Fineline Cube Jan 9, 2023

The National Health Commission (NHC) has released the 10th edition of the national COVID-19 Diagnosis...

Company Drug

HutchMed’s Sovleplenib Administered to First Patient in Phase II COVID-19 Study

Fineline Cube Jan 6, 2023

On January 4, Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) administered its novel, investigational,...

Company Medical Device

Zai Lab and Novocure’s TTFields Device Shows Survival Benefit in Lung Cancer Study

Fineline Cube Jan 6, 2023

Shares in Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) and its partner Novocure...

Company Drug

Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133

Fineline Cube Jan 6, 2023

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...

Company Deals

Kactus Biosystems Partners with Bioheng for Cell Therapy Raw Materials

Fineline Cube Jan 6, 2023

Shanghai-based Kactus Biosystems, a firm specializing in target proteins and raw enzymes, has announced a...

Company Deals

Immune-Onc Therapeutics Completes $131 Million Series B Financing

Fineline Cube Jan 6, 2023

US-headquartered Immune-Onc Therapeutics, Inc. has announced the successful completion of a Series B financing round...

Company Drug

Henlius Completes First Dosing in Global Phase III Study for HanSiZhuang in LS-SCLC

Fineline Cube Jan 6, 2023

Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...

Company Deals

Singular Medical Secures Series B+ Funding for Cardiac Device Development

Fineline Cube Jan 6, 2023

Singular Medical, a Suzhou-based maker of cardiac rhythm and heart failure devices, has reportedly raised...

Company Drug

Boehringer Ingelheim Enrolls First Patient in Phase II/III Study for BI 907828

Fineline Cube Jan 6, 2023

German pharmaceutical giant Boehringer Ingelheim has announced the enrollment of the first patient in the...

Company Drug

Vcanbio’s Stem Cell Therapy VUM02 Accepted for Clinical Trial Review

Fineline Cube Jan 6, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...

Company Drug

CanSino Biologics’ mRNA Vaccine CS-2034 Shows Positive Safety and Immunogenicity Data

Fineline Cube Jan 6, 2023

China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing...

Posts pagination

1 … 603 604 605 … 692

Recent updates

  • Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement
  • Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721
  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Others

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.